INTRODUCTION
Inherited defects of protein glycosylation in man comprise a rapidly growing group of multisystemic disorders, designated 'congenital disorders of glycosylation' (CDG).
Besides multiple organ failures, the deficiencies are commonly associated with severe psychomotor and mental retardation. The characteristic biochemical feature of CDG is defective glycosylation of glycoproteins due to mutations in proteins required for the biosynthesis of N-linked glycan chains. This post-translational protein modification by transfer of sugar moieties plays an important role in folding, transport, function and stability of glycoproteins.
In the last two decades, the molecular defects of more than 40 different inherited human glycosylation disorders have been identified, including protein and lipid glycosylation † The authors wish it to be known that, in their opinion, the first three authors should be regarded as joint First Authors.
deficiencies (1) (2) (3) (4) (5) (6) (7) . Here, we describe the first patient with a deficiency of GDP-mannose:Man 3 GlcNAc 2 -PP-dolichol-a-1, 2-mannosyltransferase. The enzyme is encoded by hALG11, the human ortholog of ALG11 (for asparagine-linked glycosylation) from yeast, which catalyzes the transfer of the fourth and fifth mannose residue from GDP-mannose (GDP-Man) to Man 3 GlcNAc 2 -PP-dolichol and Man 4 GlcNAc 2 -PP-dolichol on the cytosolic side of the endoplasmic reticulum (ER) giving rise to Man 5 GlcNAc 2 -PP-dolichol ( Fig. 1) (8) . The glycosyl acceptor of ALG11, Man 3 GlcNAc 2 -PP-dolichol, is assembled by stepwise transfer of N-acetylglucosaminephosphate and N-acetylglucosamine, respectively, catalyzed by DPAGT1 and the heterodimeric ALG13 /ALG14 complex, followed by transfer of three mannose residues added by ALG1 and ALG2 mannosyltransferases (Fig. 1) . Similar to ALG11, ALG2 catalyzes the transfer of two mannose residues (8, 9) . Furthermore, recent studies in yeast indicated that ALG11, ALG1 and ALG2 form heteromeric complexes (10) . As demonstrated here, dysfunction of ALG11 leads to a new type of CDG, CDG-Ip, by affecting the assembly of the fulllength oligosaccharide Glc 3 Man 9 GlcNAc 2 -PP-dolichol that finally will be transferred onto nascent glycoproteins by the oligosaccharyltransferase complex.
RESULTS

Case report
Patient G.D. was born naturally in the 38th week of an uneventful pregnancy as second female child to healthy parents of Turkish origin. The parents of the patient are first cousins (share a set of grandparents). The patient presented with facial dysmorphisms, such as small head and high forehead with lowered hairline. In the first weeks of life, the girl started suffering from refusal to feed, recurrent vomiting and muscular hypotonia, especially of the head and trunk region. Convulsions of the body and oscillations of body temperature were frequent. Pupil reaction and fixation were delayed and she showed no blink reaction. Between the fourth and eighth months of life, the girl developed fat pads on breast, neck and temples as well as inverted nipples. Owing to the results of a 'brainstem electric response audiometry' (BERA), she was supposed to be afflicted with deafness. Development was severely retarded due to an ongoing insufficiency of ingestion caused by persistent vomiting and bleeding of stomach. Electroencephalography, performed on the basis of frequent and difficult-to-treat seizures, showed generalized epileptic activity in both hemispheres. Despite elevated levels of lactate (3.9 mmol/l), ammonia (101 mg/dl) and prolactin (3626 mE/ml) and a reduced amount of antithrombin (37%), extensive laboratory investigations failed to reveal any significant metabolic or hematological abnormality. The patient died at 2 years of age. Assuming a glycosylation defect as cause for the patient's deficiency, initial investigations on the glycosylation state of serum transferrin by isoelectric focusing and SDS-PAGE were carried out.
While work on this new CDG-type was on progress, another child was born on term to the family. At the age of 6 weeks, the boy presented with recurrent vomiting and muscular hypotonia. Despite a slight veined complexion, no dysplastic stigmata were observed. Electroencephalography showed a generalized epileptic activity and during the phases of crying, a considerable opisthotonus appeared. Like his sister, he is supposed to be afflicted with bilateral deafness after accomplishing a BERA examination. By sequence analysis, it was found (see below) that both patients had a c.T257C mutation in the hALG11 gene in the homozygous state. Since only patient-derived fibroblasts were available from patient G.D., all further experiments were performed with material from this child.
Isoelectric focusing and SDS -PAGE of serum transferrin
Isoelectric focusing of serum transferrin, the standard diagnostic procedure for CDG, showed an increased amount of di-and asialo-transferrin at the expense of tetrasialotransferrin, a pattern characteristic of CDG-I (Fig. 2, top) . Size determination of transferrin by SDS -PAGE and western blotting revealed the presence of faster migrating forms, suggesting the absence of either one or both of the two N-glycan chains that are normally present on transferrin (Fig. 2, bottom) . 
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Determination of phosphomannomutase and phosphomannose isomerase activities
Activities of phosphomannomutase (PMM) and phosphomannose isomerase (PMI) were measured in patient-derived fibroblasts and were found to be normal, excluding CDG-Ia and CDG-Ib, respectively (data not shown).
Analysis of dolichol-and protein-derived oligosaccharides
In contrast to controls (Fig. 3A) , HPLC analysis of dolichollinked oligosaccharides of patient-derived fibroblasts, labeled with [2] [3] H]mannose, revealed two weak accumulations of shortened oligosaccharides, which co-eluted with Man 3 GlcNAc 2 and Man 4 GlcNAc 2 standards, respectively, whereas the level of Glc 3 Man 9 GlcNAc 2 was reduced (Fig. 3B) . To examine the more hydrophobic dolichol-linked oligosaccharides with shorter sugar chains that in part may have been missed by extraction with chloroform/methanol/water (10:10:3), we analyzed the chloroform/methanol (3:2) extract also by thin layer chromatography. In both control (Fig. 3E ) and patient-derived fibroblasts, dolichol-phosphate-mannose was detectable besides non-migrating material at the origin. In contrast, in the case of the patient (Fig. 3F) , two additional small peaks were detected, assumed to be Man 3 GlcNAc 2 -PP-Dol and Man 4 GlcNAc 2 -PP-Dol, confirming the accumulations of shortened dolichol-linked oligosaccharides in Figure 3B .
In order to determine whether these shortened dolichollinked oligosaccharides are translocated to the ER lumen and transferred onto newly synthesized glycoproteins by the oligosaccharyltransferase complex, [2] [3] H]mannose-labeled oligosaccharides were released from glycoproteins by peptide N-glycosidase F digestion and analyzed by HPLC. N-Glycans from control fibroblasts eluted mainly at the positions of Glc 1 Man 9 GlcNAc 2 and Man 9 GlcNAc 2 standards (Fig. 3C ). In the case of the patient, N-glycans released from newly synthesized glycoproteins showed a comparable oligosaccharide profile, however, with a reduced amount of N-glycans compared with the control (Fig. 3D) .
Analysis of radiolabeled free glycan chains in the cytoplasm
Since there was no transfer of the truncated lipid-linked oligosaccharides Man 3 GlcNAc 2 -PP-Dol and Man 4 GlcNAc 2 -PP-Dol onto proteins detectable, we analyzed whether these truncated LLOs are released into the cytoplasm as radiolabeled free glycan chains. In the cytosolic fractions of control fibroblasts, we detected Man 9 GlcNAc 2 and Man 8 GlcNAc 2 and also a comparable amount of two shorter mannose-containing structures, which could be identified as Man 2 GlcNAc 2 and an unidentified additional fraction (Fig. 4A) . Free radioactive mannose elutes in the first peak. In patient-derived cytosolic fractions, the bulk of free oligosaccharides co-eluted with this free mannose, whereas the longer glycan chains detected in the control were reduced to 50% (Fig. 4B) .
Deficiency of GDP-Man:Man 3 GlcNAc 2 -PP-dolichol-a-1,2-mannosyltransferase in patient-derived fibroblasts
The accumulations of Man 3 GlcNAc 2 -PP-Dol and Man 4 GlcNAc 2 -PP-Dol in the patient suggested a biochemical defect in the elongation of these intermediates. We therefore established an in vitro assay that allowed to measure reactions from GlcNAc 2 -PP-Dol to Man 5 GlcNAc 2 -PP-Dol. When a solubilized extract from microsomes as enzyme source was incubated with GDP-Man and [ (Fig. 5A) . In contrast, when using the solubilisate from the patient, only elongation to Man 3 GlcNAc 2 -PP-Dol occurred (Fig. 5B) , indicating that in the patient biosynthesis of dolichol-linked oligosaccharides is defective at the step, adding the fourth and as a consequence also the fifth mannose residue, catalyzed both by the ALG11 mannosyltransferase.
Genetic analysis of hALG11
Sequence analysis of human ALG11 cDNA revealed homozygosity for transition c.T257C in both patients. This mutation leads to the substitution of leucine residue 86 by a serine residue (p.L86S). Sequence analysis of the corresponding exon 2 of the hALG11 gene confirmed the mutational status of the patient as well as heterozygosity for the parents (data not shown). In 100 control alleles, the mutation has not been found.
Retroviral complementation of hALG11 in patient-derived fibroblasts
To confirm deficiency of hALG11 as the primary cause of the glycosylation defect of patient G.D., we expressed hALG11 cDNA from a healthy control person in patient-derived fibroblasts using a retroviral expression system. As control the vector pLNCX2 (mock) was transduced into control and patient-derived fibroblasts, showing no effect on the LLO profile (data not shown). Transduction of the patient's fibroblasts with wild-type hALG11 led to complete disappearance of Man 3 GlcNAc 2 -PP-dolichol and Man 4 GlcNAc 2 -PP-dolichol and to enhancement of the amount of full-length dolichollinked oligosaccharides ( Fig. 6A-C) .
Complementation of Dalg11 yeast by hALG11
To verify the complementation results in patient fibroblasts and to demonstrate that hALG11 is the ortholog of yeast ALG11, we introduced cDNAs encoding wild-type hALG11 or the hALG11(L86S) mutation into the Dalg11 yeast strain. We found that only transformation with wild-type, but not with mutant hALG11, led to normalization of metabolically [2] [3] H]mannose-labeled dolichol-linked oligosaccharides ( Fig. 7A and B). It should be noted that in alg11 yeast, besides accumulation of Man 3 GlcNAc 2 -PP-Dol, there was some further elongation of the a1,6-arm to aberrant Man 6/7 GlcNAc 2 -PP-dolichol isomer species not synthesized in the wild-type (marked by asterisks in Figure 7B and C) by luminal ER mannosyltransferases (11) . Complementation by hALG11 was also evident, when the growth behaviour of Dalg11 was investigated (Fig. 8) . This strain displays a growth defect at 368C. Transformation with the hALG11 from a control complemented this defect as did ALG11 from yeast. To verify the importance of the (L86S) mutation of the patient, we examined besides the hALG11(L86S) also mutants in which leucine 86 was replaced by a conservative alanine exchange or by a proline that may eventually lead to structural constraints in the protein. As can be seen in Figure 8A , substitution by alanine does not affect the function of the mannosyltransferase, whereas serine causes some residual growth that is completely abolished by the proline exchange. Finally, the glycosylation status of the vacuolar model glycoprotein carboxypeptidase Y (CPY) was assessed (Fig. 8B ). In the Dalg11 strain CPY was hypoglycosylated because of reduced transfer of truncated oligosaccharides to the protein. Transformation with control hALG11 or hALG11(L86A), but not hALG11(L86S) or hALG11(L86P) led to normalization of glycosylation of CPY in a similar manner as the growth phenotype.
Expression, localization and interaction of hALG11 (p.L86S) with hALG1 AND hALG2
To analyze the potential effects of the patient's p.L86S mutation on the expression levels of hALG11, hALG1 or hALG2, we performed western blot analyses with cell lysates from control and patient-derived fibroblasts. Since no difference was detectable for the patient compared with the control (Fig. 9 ), we assume no mutational effect of p.L86S on the expression of the mannosyltransferases mentioned above.
To further examine whether the p.L86S mutation leads to an intracellular mislocalization of the patient's hALG11 protein or to instability of the potential complex of mannosyltransferases hALG1, hALG2 and hALG11, immunofluorescence analyses were performed in patient and control fibroblasts with antibodies against hALG11 and calnexin, and accordingly with anti-hALG11 and anti-hALG1 or with antihALG11 and anti-hALG2. Since the mentioned proteins co-localize in control and patient-derived fibroblasts, it seems improbably that mutation p.L86S has an impact on 
the cellular localization of hALG11 or the stability of the mannosyltransferase complex (Fig. 10 ).
DISCUSSION
In a patient, who presented clinically with muscular hypotonia, convulsions, developmental retardation, dysmorphic signs and death in infancy, a deficiency of GDP-Man:Man 3 GlcNAc 2 -PP-dolichol mannosyltransferase, the human ortholog of Alg11 from yeast, was identified as the molecular cause. The enzymatic malfunction leads to impairment in the elongation of lipid-linked oligosaccharides at the outer leaflet of the ER, resulting in CDG-Ip, a new type of CDG. For the sake of completeness, the authors like to mention that this deficiency would be named 'ALG11-CDG' by following another nomenclature for CDG proposed in 2008 (12) , although this new naming is not yet agreed by the CDG community. 
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In several inherited human disorders (CDG-Ic to CDG-Ii, CDG-Ik, CDG-IL and CDG-In), deficiency of proteins involved in the assembly of dolichol-linked oligosaccharides lead to an accumulation of distinct shortened intermediates. In the case of patient G.D., we found by HPLC and thin layer chromatography analyses an accumulation of Man 3 GlcNAc 2 -PP-Dol and Man 4 GlcNAc 2 -PP-Dol. Nevertheless, the bulk fraction of oligosaccharides consisted of Glc 3 Man 9 GlcNAc 2 -PP-Dol, thereby indicating the leaky nature of the mutated enzyme.
The accumulation of Man 3 GlcNAc 2 -PP-Dol and Man 4 GlcNAc 2 -PP-Dol as well as the lack of mannosyltransferase activity determined in fibroblasts of the patient confirms the dual function of the hALG11 enzyme as a glycosyltransferase adding sequentially two mannose residues, as revealed from studies in Saccharomyces cerevisiae (8) . In contrast to the yeast Dalg11 strain, in which Man 3 GlcNAc 2 -PP-dolichol and Man 4 GlcNAc 2 -PP-dolichol are translocated to the ER lumen, which are further elongated to aberrant Man 7 GlcNAc 2 -PP-dolichol and Man 8 GlcNAc 2 -PP-dolichol isomers and transferred to newly synthesized glycoproteins (11) , no shortened, but reduced amounts of full-length oligosaccharides were detected on newly synthesized proteins of the patient. Possible explanations might be a somewhat different substrate specificity of the translocating ER flippase or of the oligosaccharyltransferase complex in yeast and man.
To investigate the fate of Man 3 GlcNAc 2 -PP-dolichol and Man 4 GlcNAc 2 -PP-dolichol, we analyzed free oligosaccharides in the cytoplasm. Free oligosaccharides are not only generated from misfolded glycoproteins resulting in Man 9 GlcNAc 1/2 and Man 8 GlcNAc 1/2 but also from lipid-linked oligosaccharides (13) . The lower amount of Man 9 GlcNAc 1/2 and Man 8 GlcNAc 1/2 seen in the patient is consistent with the reduced amount of transferred full-length oligosaccharides onto proteins. Released glycan chains are usually trimmed to Man 5 GlcNAc 1 for further degradation in lysosomes to Man 2 . Dolichol-phosphate is supposed to be a rate-limiting intermediate during protein glycosylation and is regenerated to start a new cycle of LLO synthesis. The huge amount of free mannose in the patient may be caused by reduced mannose usage due to the ALG11 defect or arises from another very short co-eluting truncated oligosaccharide that is missed in the control.
Biochemical findings of patient G.D. entailed genetic analysis of her and the parent's hALG11 gene, in which homozygosity for nucleotide transition c.T257C (p.L86S) was identified for the patient and carrier status for both parents. Furthermore, mutation p.L86S has also been detected in the homozygous state in a newborn brother of patient G.D., who presents with first symptoms of affection. The disease-causing effect of the mutation in the hALG11 gene was proved by complementation of the glycosylation defect in patient-derived fibroblasts by retroviral transduction of the control hALG11 cDNA and by complementing the glycosylation and growth defect of Dalg11 yeast cells.
Human ALG11 is predicted to be a transmembrane glycoprotein with two potential N-glycosylation sites on asparagine residues 257 and 273 and two transmembrane domains between amino acids 20-40 and amino acids 234-254 (CBS Prediction Server). Yeast ALG11 has four potential N-glycosylation sites, which were shown as not being used on the basis of insensitivity towards endoH (11) . Compared with human ALG11, the yeast homolog is predicted to possess only one transmembrane domain located between amino acids 21 and 41. This domain is characterized as potential signal-anchor domain for a type I membrane protein facing the long C-terminal catalytic domain to the cytosol, where mannose transfer from GDP-mannose to the dolichol-linked precursor oligosaccharide takes place. ALG11 belongs to the PFAM glycosyltransferase 1 group (GT1-PFAM, accession no. PF00534), whose members catalyze the transfer of nucleotide-activated sugars to different acceptors and possess a structure with two distinct Rossmann-like type B domains (GT-B fold), separated by a flexible hinge region, where the catalytic site is assumed. The conserved C-terminus is responsible for nucleotide-sugar binding, whereas the N-terminus shows lower conservation due to variable structures of acceptor molecules interacting with this area (14) . According to the transfer of two mannose residues catalyzed by ALG11 on the cytosolic leaflet of the ER membrane, the catalytic domain is expected to show cytosolic localization. Therefore, we hypothesize for the human ALG11 a topology, where the second predicted transmembrane domain of hALG11 possibly does not span through, but is imbedded into the leaflet of the ER. This would lead to a cytosolic localization not only of the protein domain between the two hydrophobic helices, but also of the C-terminus, coinciding with the potential catalytic domain and similar to yeast Alg2 topology proposed by Kämpf et al. (9) . Mutation p.L86S is located more to the N-terminus of hALG11 between the two hydrophobic helices at the end of a glycine-rich motif which is also conserved in all analyzed species (Fig. 11, top) . For Alg11 of S. cerevisiae, this region is described as compositional bias 'Poly-Gly', a homopolymeric stretch with over-representation of glycine residues (UniProt database). Glycine-rich loops are characteristic peptide motives for GT-B folds, one of two known structures of glycosyltransferases, showing flexibility and large conformational changes due to interactions with phosphate moieties of the respective nucleotide-activated sugar donor (14) . In alignments with the species mentioned above, the corresponding position to human leucine 86 in ALG11 always carries an aliphatic, neutral and non-polar (V, L) residue, whereas p.L86S results in the exchange of a non-polar to a polar residue in the protein (Fig. 11, top) . Comparing hALG11 position 86 with corresponding amino acids in hALG1 and hALG2 reveals that the leucine residue in this position is conserved through these three functional related mannosyltransferases (Fig. 11, bottom) , implicating its importance for functionality. Mutation p.L86S might therefore not impair catalytic activity of ALG11 itself, rather an interaction with the nucleotide-activated sugar donor GDP-Man is hypothesized. The significance of amino acid residue leucine 86 for ALG11 activity is emphasized by the fact that a conservative exchange by alanine does not affect the activity, whereas a proline residue that is expected to have a strong effect on protein structure was detrimental, when expressed in yeast. By indirect immunofluorescence, a perinuclear localization of Alg11 from yeast was shown, being characteristic for the ER (11) . Such a pattern could also be confirmed in primary fibroblasts of patient G.D. and controls. In patient-derived fibroblasts ALG11 co-localizes with the membrane bound ER marker calnexin, indicating that the p.L86S mutation does not affect ALG11 localization. Since there is evidence for physical interactions of cytosolic oriented mannosyltransferases Alg1, Alg2 and Alg11 in yeast (10), we analyzed therefore also localization of such a potential complex for impairment in patient G.D. by immunofluorescence microscopy. Co-localization of hALG1 with hALG11, and of hALG2 with hALG11, in control and patient fibroblasts points to the supposition that the complex is not affected by the p.L86S mutation. This assumption was also confirmed by the Western blot analysis, showing a comparable expression of hALG1, hALG2 and hALG11 mannosyltransferases of patient G.D. and controls.
In conclusion, mutation p.L86S in the endoplasmic reticulum mannosyltransferase hALG11 leads to accumulation of Man 3 GlcNAc 2 -PP-dolichol and Man 4 GlcNAc 2 -PP-dolichol in the index CDG-Ip patient. Since neither localization nor expression of hALG11, hALG1 or hALG2 seem to be affected, the disease-causing mechanism of p.L86S remains to be solved. Nevertheless, deficiency of hALG11 leads to a new CDG-type with fatal outcome.
MATERIALS AND METHODS
Isoelectric focusing and SDS-PAGE of serum transferrin
Isoelectric focusing and SDS -PAGE of serum transferrin were carried out as described previously (15) .
Determination of phosphomannomutase and phosphomannose isomerase activities
Analysis of PMM (deficient in CDG-Ia) and PMI (deficient in CDG-Ib) activity was carried out as described (16) .
Cell lines and cell culture
Fibroblasts from patient G.D. and controls were maintained at 378C under 5% CO 2 in 'Dulbecco's modified Eagle's medium high glucose' (DMEM-HG; PAA), supplemented with 10% fetal calf serum (FCS; PAN Biotech GmbH) and 100 U/ml Penicillin/Streptomycin (Pen/Strep; PAA). The ecotropic packaging cell line FNX-Eco (ATCC) and the amphotropic packaging cell line retroPack PT67 (Clontech) were cultured in DMEM-HG containing 2 mM L-glutamine (PAA), 100 U/ml Pen/Strep and 10% FCS, which was heat-inactivated at 568C for 30 min, at 378C under 5% CO 2 , unless otherwise stated.
Analysis of dolichol-and protein-linked oligosaccharides
Prior to labeling, 1.2 Â 10 6 fibroblasts of a control and patient G.D. were plated onto 60 mm culture dishes and grown for 36 h in DMEM-HG. To starve cells, medium was changed after 36 h incubation in DMEM-HG to 'DMEM no glucose' (DMEM-NG, without glucose and pyruvate; Invitrogen), supplemented with 0.5 mM glucose, 10% FCS and 100 U/ml Pen/ Strep 12 h prior to labeling. Labeling of cells, extraction and analysis of dolichol-and protein-linked oligosaccharides were performed as described (16) .
In vivo labeling of dolichol-linked oligosaccharides in yeast with [2] [3] H]mannose and analysis by HPLC were performed as described by Knauer and Lehle (17) . Dalg11 cells transformed with hALG11 from a control person or the patient were grown in yeast nitrogen base (YNB) medium containing 0.5 M KCl overnight at 258C. Subsequently, cells were labeled with 100 mCi [2- 3 H]mannose at 258C for 15 min in YPD without glucose.
Analysis of radiolabeled free glycan chains in the cytoplasm
For analysis of free glycan chains in the cytoplasm, labeled cells were scraped into 2 ml of ice-cold methanol and lyzed by sonification as described (16), followed by centrifugation for 10 min at 1000g at 48C. Cytosolic free oligosaccharides in the supernatant were separated from proteins by elution with water from C18 Sep Pak cartridges (Waters), dried under vacuum and analyzed by HPLC. The pellet was resuspended in 2 ml ice-cold methanol for subsequent extraction of dolichol-and protein-linked oligosaccharides as described (16) .
Enzyme assay
To diagnose the Alg11 defect, an enzyme assay was used to measure the elongation of GlcNAc 2 -PP-Dol to Man 5 GlcNAc 2 -PP-Dol. The reaction contained 13 mM Tris -HCl, pH 7.1, 9 mM MgCl 2 , 0.8 mM DTT, 0.14 mM Na-EDTA, 0.13% Nonidet P-40, 4 mM potassium citrate, pH 6.9, [
14 C]GlcNAc 2 -PP-Dol (4000 c.p.m.), 0.2 mM GDP-Man and solubilized enzyme (equivalent to 0.05 mg membrane protein) in a final volume of 0.06 ml. After incubation at 378C for 8 min, the reaction was stopped by chloroform/methanol/water to give a final ratio of 2:1:1 (by vol.). The reaction was processed by phase partitioning (18) using an upper phase of chloroform/methanol/ water of 1:32:48 (by vol.) and by collecting both lower and interphases. Products were analyzed by HPLC after cleavage of the carbohydrate from the lipid portion by mild acid hydrolysis as described in Knauer and Lehle (17) . Solubilized enzyme was obtained from a microsomal membrane fraction of fibroblasts of a control and patient G.D., prepared as described (19) , except that microsomes were suspended in 20 mM Tris-HCl, pH 7.1, 10 mM MgCl 2 and 1 mM DTT. For solubilization, the protein concentration was adjusted to 7 mg/ml and 1% 
Mutation analysis
Total RNA was extracted from controls and patient-derived fibroblasts using the RNAeasy kit (Qiagen). First-strand cDNA of human ALG11 was synthesized from 0.5 mg of total RNA with Omniscript reverse transcriptase (Qiagen) and primer R1 (5 0 -CCACTAGTTCTTCCTGGTGGC-3 0 ). ALG11 cDNA was amplified with primers F1 (5 0 -GTGAAG CGTTTCCTGAGTTCG-3 0 ) and R1 with the HotStar-TaqPolymerase kit (Qiagen), pre-incubated at 958C for 15 min, followed by 30 cycles with 1 min at 948C, 0.5 min at 558C and 3 min at 728C. PCR products were analyzed on 1% agarose gels and extracted with the QIAquick gel extraction kit (Qiagen) for subcloning into the pGEM-T-easy vector (Promega). To verify the mutation, genomic DNA was prepared from control and patient-derived fibroblasts and from leukocytes of the patient's parents by standard procedures (21) . In a first round of PCR, exon 2 of hALG11 was amplified from 100 ng template with primers Ex2-F1 (5 0 -GTTAGCAG ACTCGTTAAAGACAA-3 0 ) and Ex2-R1 (5 0 -GTGCCACTG CACTCCAGCC-3 0 ) using PfuTurbo DNA-Polymerase (Stratagene) with a pre-incubation at 958C for 1 min followed by 30 cycles with 1 min at 948C, 0.5 min at 558C and 1 min at 688C. Further amplification was carried out with nested primers Ex2-F2 (5 0 -GTTACTAATATATAAAGTAGATATG TA-3 0 ) and Ex2-R2 (5 0 -GAAATGGAACAATATAGCAAAT TAG-3 0 ). PCR products were analyzed on a 1% agarose gel and extracted with the QIAquick gel extraction kit. Sequence analysis of PCR products and plasmids was performed by dyedetermined cycle sequencing with primers pUC M13 forward, pUC M13 reverse (Stratagene), F1, F2 (5
Site-directed mutagenesis A 1.5 kbp fragment of wild-type hALG11 cDNA representing the coding sequence (nt 1-1479) was amplified by PCR with primers F2-NotI (5 0 -GACGCGGCCGCCACCATGGCG GCCGGCGAAAGGAG-3 0 ) and R2-NotI (5 0 -CGACTCGAG TTACTTAAATAACTTTTCCACAGATG-3 0 ). Fifty nanograms of template were used in a volume of 50 ml with PfuTurbo DNA-Polymerase. Pre-incubation was performed at 958C for 1 min followed by 28 cycles with 0.5 min at 948C, 0.5 min at 558C and 3 min at 688C. The resulting fragment was digested with NotI (MBI-Fermentas), purified and cloned into MoMuLV-derived vector pLNCX2 (Clontech), leading to plasmid pLNCX2-ALG11 control.
Production of retroviruses
One day before transfection, 0.5 Â 10 6 FNX-Eco cells were seeded onto 60 mm dishes. Transient transfection by FuGENE-HD reagent (Roche Applied Science) was carried out according to the manufacturers' protocol with 1 mg of pLNCX2 vector (mock) and pLNCX2-ALG11 control, respectively. Further processing was carried out as described (19) .
Yeast methods and complementation of Dalg11 cells by hALG11
The cDNAs of hALG11 from a control and patient G.D. were digested with HindIII and BamHI and subsequently cloned into vector pVT100. Thereby ALG11 was put under the control of the constitutive ADH1 promotor. Plasmids were transformed into Dalg11 null mutant BAY2402 (MATa ura3-1 his3-11 leu2-3_12, trp1D2 ade2-1 can1-100 ALG11::kanD MX4) using standard techniques. Yeast cells were grown in YPD medium (1% yeast extract, 2% bactopeptone, 2% glucose) or in selective YNB medium (0.67% YNB, 0.5% casamino acids, 2% glucose) supplemented with amino acids and nucleotide bases, as required. In the case of Dalg11, the medium contained, if not indicated otherwise, 0.5 M KCl also. For growth complementation of Dalg11 cells by hALG11, transformants were grown in selective liquid medium overnight at 258C to mid-logarithmic phase, and 3 ml of serial 10-fold dilutions were spotted on YPD agar plates, containing 0.5 M KCl, starting with 10 6 cells, and grown at 368C for 2 days. Analysis of the glycosylation status of carboxypeptidase Y was analyzed by Western blotting of the cytosolic fraction obtained by cell breakage with glass beads and centrifugation at 45 000g.
Antibodies
Primary antibodies against human ALG11 (Aviva Systems Biology, rabbit anti-human), ALG2 and ALG1 (Aviva Systems Biology, mouse anti-human) were used in dilution of 1:1000 in 5% milk powder in phosphate-buffered saline Tween-20 (0.1% in PBST) for Western blotting and of 1:250 in PBST for immunofluorescence analysis. Primary antibody against calnexin (BD Bioscience, mouse anti-human) was used in a dilution of 1:500 in PBST for immunofluorescence. As secondary antibody, a horseradish peroxidase conjugate was used (Dianova, goat anti-rabbit; Santa Cruz, goat antimouse) in a dilution of 1:10 000 in PBST. Fluorochromeconjugated antibodies (Cy2: GE Healthcare, goat anti-mouse; Cy3: GE Healthcare, goat anti-rabbit) were used for immunofluorescence, diluted 1:400 in PBST.
Western blotting
Patient and control fibroblasts were lysed in Tris-buffered saline (TBS)/1% Triton X-100/protease inhibitor mix for 30 min on ice, followed by sonification and vortexing. After centrifugation (16 000g, 48C for 20 min), 30 mg protein of the supernatant was separated on a denaturing 10% SDSpolyacrylamidegel and transferred to a nitrocellulose membrane by semi-dry Western blotting. Membranes were blocked with 5% milk powder in PBST for 1 h at room temperature and incubated with anti-hALG11, hALG2 or hALG1 antibodies in 5% milk powder in PBST overnight at 48C, respectively. The membranes were washed three times with PBST for 20 min at RT and incubated with HRP-coupled secondary antibody for 1 h at room temperature. After washing the membranes, visualization was performed by adding chemiluminescence reagent (Pierce).
Immunofluorescence
One day before preparation, 6 Â 10 4 fibroblasts from a control and the patient were seeded on glass cover slips. Immunofluorescence was carried out as described previously (22) . Cells were incubated with antibodies against hALG11, hALG2, hALG1 and ER marker protein calnexin at 48C overnight, respectively. After incubation with secondary antibodies conjugated to fluorochromes Cy2 and Cy3, cells were mounted with Vectashield DAPI (Vector) and analyzed using a confocal fluorescence microscope.
